Effects of 153Sm-ethylenediaminetetramethylene phosphonate on physeal and articular cartilage in juvenile rabbits.
Previous studies reported that the radiopharmaceutical (153)Sm-ethylenediaminetetramethylene phosphonate ((153)Sm-EDTMP) is an effective component of multimodality therapy for the treatment of primary bone tumors. Therefore, (153)Sm-EDTMP may prove to be an integral component of therapy for the treatment of juvenile osteosarcoma. The purpose of this study was to determine the effects of intravenous administration of (153)Sm-EDTMP on the developing physeal and articular cartilage of healthy, juvenile rabbits.


METHODS
Sixteen healthy 8-wk-old male New Zealand White rabbits were assigned to 1 of 2 groups: treatment (n = 12) and control (n = 4). (153)Sm-EDTMP was administered to the treatment group at 37 MBq/kg (1 mCi/kg). The animals were sacrificed at 16 wk of age, and the physeal cartilage of multiple bones was evaluated by use of histologic, immunohistochemical, and histomorphometric analyses. The overall changes in the lengths of the radius and the tibia between control and treatment groups were calculated and compared. Measurement data were combined for each group, and means +/- SEMs were determined.


RESULTS
Significant differences in radial bone growth were present between the groups. Histologically, the physes of the treatment group were disrupted and chaotic in appearance. Significant differences in the immunoreactivity of type X collagen and matrix metalloproteinase-13 were seen between the groups, as these markers were positively expressed in the zone of hypertrophy of the control rabbits.


CONCLUSIONS
Clinically significant damage to the developing physeal cartilage may occur as a result of the intravenous administration of (153)Sm-EDTMP at the dose studied.
Essman
Stephanie C
SC
Department of Medicine and Surgery, University of Missouri-Columbia, 65211, USA. essmans@missouri.edu
Lattimer
Jim
J
Cook
James L
JL
Turnquist
Sue
S
Kuroki
Keiichi
K
D000818:Animals; D001846:Bone Development / Q000187:drug effects / Q000528:radiation effects*; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects*; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects*; D006132:Growth Plate / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects*; D007275:Injections, Intravenous; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000633:toxicity*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000633:toxicity*; D011817:Rabbits; D012016:Reference Values
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam